Gold consolidated in the early Asian session amid mixed signals.

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Molina Healthcare, Inc. (NYSE: MOH) between February 5, 2025 and July 23, 2025, both dates inclusive (the "Class Period"), of the important December 2, 2025 lead plaintiff deadline. So what: If you purchased Molina securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Dulux paint maker Akzo Nobel NV is in talks to merge with paintmaker Axalta Coating Systems , Bloomberg News reported on Monday, citing sources familiar with the matter.

Vanda's Tradipitant Study Success Positions it as Key Adjunct in $50B+ Global GLP-1 Agonist Market WASHINGTON , Nov. 17, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of nausea and vomiting induced by GLP-1 receptor agonist Wegovy® in overweight and obese adults. This study, which pre-treated patients with either tradipitant or placebo before administering a 1 mg injection of Wegovy®, a dose that …

Gladstone Capital (GLAD) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.5 per share a year ago.

Warren Buffett's Berkshire Hathaway is making a big bet on one of the hottest tech stocks.

Since its 2024 merger, Trump Media has reported low quarterly revenues with no growth. Operating expenses, meanwhile, have been larger and have increased.

Whirlpool's NYSE: WHR stock downtrend may not be over; however, the technical, fundamental, and market forces are aligning, suggesting downside is severely limited and the upside potential is robust.

Helmerich & Payne (HP) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.26. This compares to earnings of $0.76 per share a year ago.

NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline. So what: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

A partnership including: REDF, SRC LCM Partners LONDON , Nov. 17, 2025 /PRNewswire/ -- Under the patronage and presence of His Excellency Mr. Majed bin Abdullah Al-Hogail, Minister of Municipal and Rural Affairs and Housing and Chairman of the Board of the Real Estate Development Fund, the Real Estate Development Fund (REDF) and the Saudi Real Estate Refinance Company (SRC), announced the signing of a tripartite partnership with LCM Partners.

It's been a very strong quarter for big tech earnings, but that meant much for the share prices of the season's earnings beaters.

The central question facing investors heading into 2026 is whether market performance will finally extend beyond the handful of megacap technology companies that have dominated returns for the past three years.

XPeng delivered a standout Q3'25, with sales up over 100% and EV deliveries surging 149% year-over-year. XPEV's affordable Mona EV lineup drove record volumes, while the company pushes into robotaxi and humanoid robot markets, boosting its tech profile. Despite strong sales and improving margins, XPEV remains unprofitable, but forecasts a small Q4 profit and holds a solid cash position.

Anixa Biosciences, Inc. ( ANIX ) Discusses Differentiated CAR-T Therapy and Breast Cancer Vaccine Clinical Programs November 11, 2025 2:00 PM EST Company Participants Amit Kumar - CEO, Chairman & Co-Chair of CBAB Conference Call Participants Robert Sassoon - Water Tower Research LLC Presentation Robert Sassoon Water Tower Research LLC Hello, everybody. I'm Robert Sassoon.

BioNTech SE ( BNTX ) Discusses Oncology Innovation Strategy, Combination Therapies and Personalized Cancer Immunotherapies November 11, 2025 9:00 AM EST Company Participants Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Özlem Türeci - Co-Founder, Chief Medical Officer & Member of Management Board Ilhan Celik Michael Wenger Ramón Zapata-Gomez - CFO & Member of Management Board Douglas Maffei - Vice President of Strategy & Investor Relations Annemarie Hanekamp - Chief Commercial Officer & Member of Management Board Conference Call Participants Daina Graybosch - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Jay Lee …

LifeMD, Inc. (LFMD) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.14 per share a year ago.

BP was responding to a release of refined products on the Olympic Pipeline System east of Everett, Washington, and had partially restored part of the system, the company said on Monday.

LONG BEACH, Calif.--(BUSINESS WIRE)--Molina Healthcare, Inc. (NYSE: MOH) (the “Company”) today announced that it priced $850 million aggregate principal amount of its 6.500% senior notes due 2031 (the “Notes”) to be sold in a private offering to individuals reasonably believed to be “qualified institutional buyers” pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and to certain non-U.S. persons outside the United States in reliance on Regulation S under.

LOS ANGELES & BOSTON--(BUSINESS WIRE)--Vida Ventures (“Vida”), a next-generation life sciences venture firm, today announced its fourth major Vida portfolio acquisition of 2025, capping an unprecedented year of strategic exits and reinforcing the firm's disciplined, science-first approach to company building and investing. Earlier today, Halda Therapeutics announced its acquisition by Johnson & Johnson (NYSE: JNJ) for $3.05 billion, marking a historic moment for the Vida III portfolio. Hald.